Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)
Bristol Myers Squibb's (CELG-RI) quarterly Construction in Progress came in at $1.3 billion in Q2 2026, down 26.41% year-over-year from $1.8 billion in Q2 2025, and down 15.9% quarter-over-quarter from $1.5 billion in Q1 2026.
Analysis
Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Construction in Progress for 12 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Construction in Progress fell 26.41% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 26.41% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 6.16% from the prior year.
- Construction in Progress was $1.3 billion for Q2 2026 at Bristol Myers Squibb, down from $1.5 billion in the prior quarter.
- Over five years, Construction in Progress peaked at $1.8 billion in Q2 2025 and troughed at $800.0 million in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Construction in Progress.
- Across the five-year window, Construction in Progress surged 54.14% in 2022 and dropped 26.41% in 2026, its largest moves.
- Over 5 years, Construction in Progress stood at $1.1 billion in 2022, then climbed by 2.09% to $1.1 billion in 2023, then soared by 41.86% to $1.5 billion in 2024, then climbed by 6.16% to $1.6 billion in 2025, then dropped by 19.95% to $1.3 billion in 2026.
- The last three Construction in Progress figures came in at $1.3 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.46 Bn | 621.70 Bn | 17.26 Bn | - |
| 2 | AbbVie | 447.01 Bn | 440.44 Bn | 12.70 Bn | - |
| 3 | Merck | 358.21 Bn | 351.07 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.54 Bn | 259.85 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.67 Bn | 144.97 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.86 Bn | 42.86 Bn | - | - |
| 8 | Incyte | 24.60 Bn | 20.06 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn | - |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn | 1.30 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 973.00 Mn |
| Jun 30, 2022 | 850.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 764.00 Mn |
| Sep 30, 2021 | 695.00 Mn |